drugset / Trial / NCT04513860

Cenobamate Expanded Access Program (EAP)

NCT04513860

Expanded access Approved for marketing SK Life Science, Inc.

Summary

This Cenobamate Expanded Access Program (EAP) is designed to continue providing treatment with Cenobamate (YKP3089) to patients with partial-onset epilepsy that were enrolled in the SK Life Science clinical trial YKP3089C013, YKP3089C017 or YKP3089C021.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Cenobamate Small molecule

Indications